Factor 8 Deficiency Treatment
Treatment for hemophilia A often includes intravenous infusions of factor 8 and fresh frozen plasma. Other treatments include the use of desmopressin and antifibrinolytic agents. Gene therapy for hemophilia A remains experimental.
Treatment for hemophilia A includes:
- Factor 8 for hemophilia A
- Factor VIII pooled plasma (ultrapure preparations recommended)
- Factor VIII recombinant products
- Fresh frozen plasma for hemophilia A
- Can cause a transient increase in factor 8 in the bloodstream
- Coagulation Factor VIIa (recombinant)
- Gene therapy for hemophilia A:
- An experimental treatment that involves introducing genetic material (DNA or RNA) into a person's cells to fight disease.
Factor 8 Deficiency Questions For Doctor
The following are some important questions to ask before and after the treatment of hemophilia A.
Questions to ask before treatment:
- What are my treatment options?
- What are the risks associated with treatment?
- Do I need to stay in the hospital?
- How long will I be in the hospital?
- What are the complications I should watch for?
- How long will I be on medication?
- What are the potential side effects of my medication?
- Does my medication interact with nonprescription medicines or supplements?
- Should I take my medication with food?
Questions to ask after treatment:
- Do I need to change my diet?
- Do I need to lose weight?
- Are there any medications or supplements I should avoid?
- When can I resume my normal activities?
- When can I return to work?
- Do I need a special exercise program?
- Will I need physical therapy?
- Will I need occupational therapy?
- What else can I do to reduce my risk for complications?
- What else can I do to reduce my risk for having this problem again?
- How often will I need to see my doctor for checkups?
- What local support and other resources are available?
Factor 8 Deficiency Specialist
Continue to Factor 8 Deficiency Home Care
- Dunn AL, Abshire TC. Recent advances in the management of the child who has hemophilia. Hematol Oncol Clin North Am. 2004 Dec;18(6):1249-76, viii. 
- Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr. 2004 Nov;145(5):628-34. 
- Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol. 2004 Oct;77(2):187-93. 
- Manco-Johnson M. Hemophilia management: optimizing treatment based on patient needs. Curr Opin Pediatr. 2005 Feb;17(1):3-6. 
- Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood. 2004 Dec 1;104(12):3494-500.